US 6,982,272 B2
Compounds useful as reversible inhibitors of cysteine proteases
Michel Jose Emmanuel, Danbury, Conn. (US); Eugene R. Hickey, Danbury, Conn. (US); Weimin Liu, Shelton, Conn. (US); Denice Mary Spero, West Redding, Conn. (US); Sanxing Sun, Danbury, Conn. (US); David S. Thomson, Ridgefield, Conn. (US); Yancey David Ward, Sandy Hook, Conn. (US); and Erick Richard Roush Young, Danbury, Conn. (US)
Assigned to Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Conn. (US)
Filed on Apr. 24, 2003, as Appl. No. 10/422,473.
Application 10/422473 is a division of application No. 10/001134, filed on Nov. 02, 2001.
Application 10/001134 is a division of application No. 09/655351, filed on Sep. 08, 2000, granted, now 6,420,364.
Claims priority of provisional application 60/153738, filed on Sep. 13, 1999.
Claims priority of provisional application 60/222900, filed on Aug. 03, 2000.
Prior Publication US 2003/0225270 A1, Dec. 04, 2003
Int. Cl. A61K 31/445 (2006.01); C07D 213/02 (2006.01); C07D 409/12 (2006.01)
U.S. Cl. 514—318 5 Claims
 
1. A compound selected from:
4-Acetylamino-N-[1-(4-cyano-1-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl]-benzamide;
4-Acetylamino-N-[1-(4-cyano-1-methyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butyl]-benzamide;
4-Acetylamino-N-[1-(1-benzyl-4-cyano-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl]-benzamide;
4-Acetylamino-N-[1-(4-cyano-1-isopropyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl]-benzamide;
N-[1-(4-cyano-1-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl]-benzamide;
4-(Acetylamino-methyl)-N-[1-(4-cyano-1-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl]-benzamide;
N-[1-(4-cyano-1-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl]-isonicotinamide;
5-Chloro-thiophene-2-carboxylic acid[1-(4-cyano-1-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl]-amide;
4-Chloro-N-[1-(4-cyano-1-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl]-benzamide;
N-[1-(4-cyano-1-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl]-3-phenoxy-benzamide;
N-[1-(4-cyano-1-methyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butyl]-benzamide;
N-[1-(4-cyano-1-methyl-piperidin-4-ylcarbamoyl)-2-cyclohexyl-ethyl]-4-fluoro-benzamide;
N-[1-(4-cyano-1-methyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butyl]-4-methanesulfonylamino-benzamide and
4-Chloro-N-[1-(4-cyano-1-propyl-piperidin-4-ylcarbamoyl)-3,3-dimethyl-butyl]-benzamide
or the pharmaceutically acceptable acceptable salts, esters, tautomers, individual isomers and mixtures of isomers thereof.